buyWeak

Mark W Kroll bought $99k of HAE

director at HAEMONETICS CORP. 1,400 shares at an average of $70.56, traded Nov 10, 2025, filed Nov 12, 2025.

Conviction score

Value

$99k

1,400 shares

Holdings after

24,757

+6% from before

From 52-week low

no price yet

From 52-week high

no price yet

Score components

Role
Director
+15
Trade size
$99k at market
+10
Relative to holdings
Holdings up 6%
+3
Price context
No price history yet
0
Cluster
No other insider buying within 14 days
0
Repeat buying
First buy in 90 days
0
Track record
Too few past buys to judge (0 with prices)
0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +14.2%, 3m -21.4%, 6m -22.0%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

HAEOct 9, 2026 · close 118.69

Since filing Nov 12, 2025: +62.3%SPY +15.2% · excess +47.2%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000313143-25-000078, as filed. Open on EDGAR

Date	Transaction	Shares	Price	Value	Holdings after	Filed
Nov 10, 2025	POpen-market purchase Common Stock	+1,400	$70.56	$99k	24,757	Nov 12, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.